T he U.S. FDA on Wednesday warned about a software glitch found in the Tandem Diabetes' (NASDAQ:TNDM) t:slim X2 insulin pump, ...

RBC expects 51% gross margins in 2024, with the Mobi pump launch driving long-term profitability. RBC Capital Markets initiated coverage on Tandem Diabetes Care, Inc. TNDM, a global insulin ...

Tandem Diabetes Care has announced that its t:slim X2 insulin pump, featuring Control-IQ automated insulin delivery ...

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that its t:slim X2 insulin pump with Control-IQ automated insulin delivery ...

RBC Capital Markets initiated coverage on Tandem Diabetes Care ... the rise of GLP-1s class drugs is not a major threat to insulin pump adoption. GLP-1 drugs such as Novo Nordisk A/S‘ (NYSE ...

the stringent testing the EU requires of pump manufacturers meant Tandem's product needed some time to catch up. Eli Lilly and Tandem teamed up to test the former's insulin product with the latter ...

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that its t:slim X2 insulin pump with Control-IQ automated insulin delivery (AID) ...

Research on CSII therapy began in the late 1970s, with a strong resurgence in the 1990s after technological advances in blood glucose monitoring devices and insulin delivery systems. In the ...

RBC Capital Markets initiated coverage on Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin ...

SAN DIEGO, September 19, 2024--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that its t:slim X2 insulin pump ...

Objective: To evaluate the safety and effectiveness of insulin pump therapy in children and adolescents with type 1 diabetes. Research Design and Methods: All 95 patients who began insulin pump ...